Actinium Pharmaceuticals
ATNM
61 hedge funds and large institutions have $8.23M invested in Actinium Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 28 reducing their positions, and 10 closing their positions.
11,200% more call options, than puts
Call options by funds: $113K | Put options by funds: $1K
7% more capital invested
Capital invested by funds: $7.66M → $8.23M (+$570K)
1.06% less ownership
Funds ownership: 17.55% → 16.5% (-1.1%)
3% less funds holding
Funds holding: 63 → 61 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
64% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$320K |
| 2 |
Two Sigma Investments
New York
|
+$306K |
| 3 |
GWP
Gen-Wealth Partners
Zeeland,
Michigan
|
+$178K |
| 4 |
Renaissance Technologies
New York
|
+$129K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$204K |
| 2 |
BlackRock
New York
|
-$170K |
| 3 |
State Street
Boston,
Massachusetts
|
-$156K |
| 4 |
CFD
Creative Financial Designs
Kokomo,
Indiana
|
-$153K |
| 5 |
Goldman Sachs
New York
|
-$128K |
ATNM Hedge Fund Activity: Q3 2025 in Review
61 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2025, worth a combined $8.23M — up 7.4% from $7.66M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATNM and 9 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 10 added.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $320K. The largest seller was Jane Street, cutting an estimated $204K.
- 61 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2025, down from 63 in Q2 2025.
- Funds reported $8.23M of Actinium Pharmaceuticals stock for Q3 2025, up 7.4% quarter-over-quarter.
- 9 funds opened new Actinium Pharmaceuticals positions in Q3 2025 and 10 closed out, a net change of -1 holder.
- The largest Actinium Pharmaceuticals buyer in Q3 2025 was Two Sigma Advisers, an estimated $320K added.
- The largest Actinium Pharmaceuticals seller in Q3 2025 was Jane Street, an estimated $204K sold.
Based on aggregated 13F filings for Q3 2025.